Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
This third era of opioids ruining thousands of US lives follows a first era of iatrogenic addiction stemming from the Harrison Act of 1914, and a second was marked by changes in pain treatment attitudes between 1950 and 1970.
AMA J Ethics. 2020;22(8):E729-734. doi:
10.1001/amajethics.2020.729.
Before a deadly heroin overdose at 27, Jean-Michel Basquiat finished an electrically vibrant skull, prompting questions today about arts donations generated by opioid profits.
AMA J Ethics. 2020;22(8):E735-738. doi:
10.1001/amajethics.2020.735.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Dr Travis Rieder discusses his own experiences with opioids and the ethical challenges of “legacy patients,” and Dr Stephanie Zaza, president of the American College of Preventive Medicine, discusses the future of opioid research priorities.
Identifying patients who are trafficked is key to caring well for these vulnerable adults and children. But labeling patients as trafficked can stigmatize patients if clinicians aren’t trained well in trauma-informed care.
AMA J Ethics. 2018;20(12):E1212-1216. doi:
10.1001/amajethics.2018.1212.